Benzomorpholine derivatives

A pharmaceutical composition comprising:

• a pharmaceutically acceptable carrier;
• and
• a benzomorpholine derivative or pharmaceutically acceptable salt thereof represented by formula I,
• wherein
• A is C2-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene,
• R1 is:
• (1) unsubstituted aryl or heteroaryl, or aryl or heteroaryl substituted with one or a plurality of substituents independently selected from the following group,
• a) C1-5 alkyl, b) C s5 alkoxy c) C3-8 cycloalkyl, d) C1-5 haloalkyl, e) phenyl, f) phenoxy, g) hydroxyl, h) C1-5 hydroxyalkyl, i) C1-5 haloalkyloxy, j) mercapto, k) C1-5 alkylthio, 1) C1-5 haloalkylthio, m) halogen, n) cyano, o) nitro, p) amino, q) C1-5 alkylamino, r) C2-10 dialkylamino, s) acyl, t) carboxyl, u) C2-6 alkyloxycarbonyl, v) mesyl, w) trifluoromethanesulfonyl, and x) tosyl;
• or
• (2) unsubstituted C1-5 alkyl, C3-8 cycloalkyl, C2-10 alkenyl, C4-10 cycloalkenyl, or C2-10 alkynyl, or C1-5 alkyl, C3-8 cycloalkyl, C2-10 alkenyl, C4-10 cycloalkenyl, or C2-10 alkynyl substituted with one or a plurality of substituents independently selected from the following group,
• a) phenyl, b) hydroxyl, c) C1-5 alkyl, d) C3-8 cycloalkyl, e) C1-5 haloalkyl, and f) halogen;
• R2 is unsubstituted aryl or heteroaryl, or aryl or heteroaryl substituted with one or a plurality of substituents independently selected from the following group,
• a) C1-5 alkyl, b) C1-5 alkoxy, c) C3-8 cycloalkyl, d) C1-5 haloalkyl, e) phenyl, f) phenoxy, g) hydroxyl, h) C1-5 hydroxyalkyl, i) C1-5 haloalkyloxy, j) mercapto, k) C1-5 alkylthio, l) C1-5 haloalkylthio, m) halogen, n) cyano, o) nitro, p) amino, q) C1-5 alkylamino, r) C2-10 dialkylamino, s) acyl, t) carboxyl, u) C2-6 alkyloxycarbonyl, v) mesyl, w) trifluoromethanesulfonyl, and x) tosyl;
• R3 is hydrogen, halogen, C1-5 alkyl, or C1-5 alkoxy;
• R4 is —X— (CH2)n-COOR5, and X is —O—, —S—, or —CH2—;
• R5 is hydrogen or C1-5 alkyl;
• and n is an integer that is 1, 2, or 3.